<DOC>
	<DOCNO>NCT03096613</DOCNO>
	<brief_summary>Based accumulate evidence show hypothyroid status associate poor prognosis among heart failure ( HF ) patient , study design evaluate whether replacement treatment levothyroxine could beneficial effect patient HF subclinical hypothyroidism . The study prospective , randomize , parallel-group trial ass efficacy safety levothyroxine replacement evidence-based HF standard therapy stable chronic heart failure patient subclinical hypothyroidism .</brief_summary>
	<brief_title>Levothyroxine Replacement Subclinical Hypothyroidism Chronic Heart Failure</brief_title>
	<detailed_description>The primary objective trial determine whether 24-week L-T4 replacement therapy , adjunct standard treatment , would improve exercise capability chronic systolic heart failure patient subclinical hypothyroidism compare standard treatment .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypothyroidism</mesh_term>
	<mesh_term>Hyperthyroidism</mesh_term>
	<criteria>Aged 18 year old , male female . Systolic heart failure New York Heart Association ( NYHA ) class IIIII . Left ventricular ejection fraction ( LVEF ) less 40 % echocardiography screen randomization . SCH ( TSH : upper limit normal ( ULN ) 10mIU/L , FT4 level within reference range ) . Having receive standard HF therapy least 2 week , reach target dose max tolerable dose . Provided informed consent . Acute heart failure acute exacerbation chronic heart failure within past 2 week . Scheduled cardiac resynchronization therapy heart transplantation . History malignant tumor life expectancy 12 month . Already medication may affect thyroid function ( LT4 , carbimazole , propylthiouracil , amiodarone , lithium ) . Pregnancy lactation period . Participation another clinical trial within past 30 day . Contraindication intolerance evidencebased therapy CHF , betablocker , angiotensinconverting enzyme inhibitor angiotensin receptor blocker . Known hypersensitivity trial treatment ( ) diluent ( applicable ) , include placebo comparator drug ( ) . Untreated adrenal insufficiency . Untreated pituitary insufficiency . Untreated thyrotoxicosis . Treatment levothyroxine must initiate patient acute myocardial infarction , acute myocarditis , acute pancarditis . Severe renal dysfunction ( eGFRâ‰¤30 ml/min/1.73m2 ) . Significant hepatic impairment ( Serum GPT &gt; 120 U/L ) . Any disorder , opinion investigator , might jeopardise subject 's safety compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>heart failure</keyword>
	<keyword>Subclinical Hyperthyroidism</keyword>
	<keyword>levothyroxine</keyword>
	<keyword>6-minute walk test</keyword>
</DOC>